EBITDA at other companies
Other financials
Where this comes from
Calculated from Stoke Therapeutics, Inc.’s reported figures.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s EBITDA?
- Stoke Therapeutics, Inc. (STOK) reported EBITDA of -$52.98M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s EBITDA changed year-over-year?
- Stoke Therapeutics, Inc.'s EBITDA decreased by 147.4% year-over-year, from $111.72M to -$52.98M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s EBITDA?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s EBITDA has grown at a -31.4% compound annual growth rate (CAGR), from -$85.09M to -$18.82M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.